Mineralys Therapeutics, Inc (MLYS) insider trading
Every open-market stock purchase and sale by Mineralys Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Brian Taylor Slingsby (Director) and 4 others sold $5.5M in the last 90 days.
- Last insider buy: Ra Capital Management L.p. (Insider), $1.4M, 7 months ago.
Last 12 months: insiders bought $8.8M (1 buy) and sold $88M (41 sales). Last close $21.47 on Oct 22, 2026.
Recent MLYS insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Oct 19, 2026 | Lonnel Coats (Director) | Bought (not open market) | — |
| Oct 19, 2026 | Lonnel Coats (Director) | Bought (not open market) | — |
| Oct 19, 2026 | Kristine Peterson (Director) | Bought (not open market) | — |
| Oct 19, 2026 | Kristine Peterson (Director) | Bought (not open market) | — |
| Sep 30, 2026 | Jon Congleton (CEO) | Sold | $1.9M |
| Sep 22, 2026 | Brian Taylor Slingsby (Director) | Sold | $3M |
| Sep 21, 2026 | Eric Warren (C-suite exec) | Sold | $209K |
| Sep 21, 2026 | Eric Warren (C-suite exec) | Bought (not open market) | — |
| Sep 15, 2026 | Daphne Karydas (Director) | Sold | $85.7K |
| Sep 15, 2026 | Daphne Karydas (Director) | Bought (not open market) | — |
| Aug 21, 2026 | Eric Warren (C-suite exec) | Sold | $193K |
| Aug 21, 2026 | Eric Warren (C-suite exec) | Bought (not open market) | — |
| Aug 10, 2026 | David Malcom Rodman (C-suite exec) | Sold | $58.8K |
| Aug 10, 2026 | David Malcom Rodman (C-suite exec) | Bought (not open market) | — |
| Aug 10, 2026 | James J. Ferguson III (C-suite exec) | Bought (not open market) | — |
| Aug 10, 2026 | James J. Ferguson III (C-suite exec) | Bought (not open market) | — |
| Jul 21, 2026 | Eric Warren (C-suite exec) | Sold | $200K |
| Jul 21, 2026 | Eric Warren (C-suite exec) | Bought (not open market) | — |
| Jul 17, 2026 | David Malcom Rodman (C-suite exec) | Sold | $11K |
| Jul 17, 2026 | David Malcom Rodman (C-suite exec) | Bought (not open market) | — |
| Jul 15, 2026 | David Malcom Rodman (C-suite exec) | Sold | $169K |
| Jul 13, 2026 | David Malcom Rodman (C-suite exec) | Sold | $388K |
| Jul 13, 2026 | Jon Congleton (CEO) | Sold | $291K |
| Jul 13, 2026 | David Malcom Rodman (C-suite exec) | Bought (not open market) | — |
| Jul 13, 2026 | David Malcom Rodman (C-suite exec) | Bought (not open market) | — |
Who's trading MLYS
- Kristine Peterson, Director: other filings, last Oct 19, 2026
- Lonnel Coats, Director: other filings, last Oct 19, 2026
- Jon Congleton, CEO: sold $16.2M (16 sales), last Sep 30, 2026
- Brian Taylor Slingsby, 10% owner: sold $46.4M (2 sales), last Sep 22, 2026
- Eric Warren, C-suite exec: sold $3.3M (4 sales), last Sep 21, 2026
- Daphne Karydas, Director: sold $926K (5 sales), last Sep 15, 2026
- James J. Ferguson III, C-suite exec: other filings, last Aug 10, 2026
- David Malcom Rodman, C-suite exec: sold $14M (38 sales), last Aug 10, 2026
- Ra Capital Management L.p., Insider: bought $8.8M (2 buys), last Mar 30, 2026
- Srinivas Akkaraju, 10% owner: other filings, last Feb 19, 2026
- Derek DiRocco, Director: other filings, last Feb 19, 2026
- Alexander M Gold, Director: sold $1.6M (5 sales), last Feb 19, 2026
- Adam Scott Levy, CFO: sold $5.7M (10 sales), last Feb 19, 2026
- Glenn Sblendorio, Director: other filings, last Feb 19, 2026
Get free alerts when an insider at Mineralys Therapeutics, Inc files a new trade →